Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Pharmaceutical Insights: Norelgestromin's R&D Progress and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Pharmaceutical Insights: Norelgestromin's R&D Progress and its Mechanism of Action on Drug Target
13 November 2023
This article summarized the latest R&D progress of Norelgestromin, the Mechanism of Action for Norelgestromin, and the drug target R&D trends for Norelgestromin.
Read →
Ankyra Therapeutics reported encouraging preclinical outcomes using ANK-101, a new immune therapy, combined with cytotoxic chemotherapy in a head and neck cancer model
Latest Hotspot
5 min read
Ankyra Therapeutics reported encouraging preclinical outcomes using ANK-101, a new immune therapy, combined with cytotoxic chemotherapy in a head and neck cancer model
13 November 2023
Ankyra Therapeutics has published encouraging preclinical results for the combined use of ANK-101, a new anchored immune therapy, and cytotoxic chemotherapy in a head and neck cancer model.
Read →
Analysis on the Clinical Research Progress of Fab Fragment
Advanced Tech.
5 min read
Analysis on the Clinical Research Progress of Fab Fragment
13 November 2023
The Fab fragment, also known as the antigen-binding fragment, is the region of an antibody that can bind with antigens.
Read →
Scholar Rock reports promising anti-tumor results from phase 1 DRAGON trial for resistant metastatic ccRCC patients. Data supports continued tolerability of SRK-181
Latest Hotspot
3 min read
Scholar Rock reports promising anti-tumor results from phase 1 DRAGON trial for resistant metastatic ccRCC patients. Data supports continued tolerability of SRK-181
13 November 2023
Scholar Rock shares fresh results from its phase 1 DRAGON trial, indicating anti-tumor potential in patients with metastatic ccRCC who are resistant to Anti-PD-1. The data also backs the ongoing tolerability of SRK-181.
Read →
Exploring Oxiconazole Nitrate's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Exploring Oxiconazole Nitrate's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
13 November 2023
This article summarized the latest R&D progress of Oxiconazole Nitrate, the Mechanism of Action for Oxiconazole Nitrate, and the drug target R&D trends for Oxiconazole Nitrate.
Read →
What are acetylcholinesterase inhibitors and how do you quickly get the latest development progress?
What are acetylcholinesterase inhibitors and how do you quickly get the latest development progress?
13 November 2023
Acetylcholinesterase (AChE), the primary cholinesterase in the body, is an enzyme catalyzing the breakdown of acetylcholine and of some other choline esters that function as neurotransmitters.
Read →
Cue Biopharma presents positive Phase 1 results for CUE-101 (Head and Neck Cancer) and CUE-102 (Wilms' Tumor 1) at SITC 2023
Latest Hotspot
3 min read
Cue Biopharma presents positive Phase 1 results for CUE-101 (Head and Neck Cancer) and CUE-102 (Wilms' Tumor 1) at SITC 2023
13 November 2023
Cue Biopharma shares encouraging results from Phase 1 studies for CUE-101 for Head and Neck Cancer, and CUE-102 for Wilms' Tumor 1 related cases, at the SITC 2023 event.
Read →
A broad-spectrum, highly specific and high-affinity antibody: Polyclonal Antibody
Advanced Tech.
5 min read
A broad-spectrum, highly specific and high-affinity antibody: Polyclonal Antibody
13 November 2023
A Polyclonal antibody (PAb) is a mixture of antibodies produced by different B cells in the body against the same antigen.
Read →
Adagene Showcases Findings Exhibiting Top-of-the-Line Therapeutic Index for Concealed Anti-CTLA-4 SAFEbody® ADG126 at 2023 SITC Event
Latest Hotspot
3 min read
Adagene Showcases Findings Exhibiting Top-of-the-Line Therapeutic Index for Concealed Anti-CTLA-4 SAFEbody® ADG126 at 2023 SITC Event
13 November 2023
At the 38th Society for Immunotherapy of Cancer Meeting, Adagene Inc. presented new data on its anti-CTLA-4 SAFEbody ADG126, revolutionizing new antibody-related therapies.
Read →
Decoding Paroxetine Mesylate: A Comprehensive Study of its R&D Trends
Drug Insights
4 min read
Decoding Paroxetine Mesylate: A Comprehensive Study of its R&D Trends
13 November 2023
This article summarized the latest R&D progress of Paroxetine Mesylate, mechanism of action for Paroxetine Mesylate, and the drug target R&D trends for Paroxetine Mesylate.
Read →
What are ACE2 inhibitor and how do you quickly get the latest development progress?
What are ACE2 inhibitor and how do you quickly get the latest development progress?
13 November 2023
ACE inhibitors are a class of drugs that work by relaxing blood vessels, inhibiting the production of the vasoconstrictor substance Angiotensin II. This results in lower blood pressure, reduced cardiac load, and decreased risk of hypertension.
Read →
Essential Tool in Interventional Radiology: Contrast Agent
Advanced Tech.
6 min read
Essential Tool in Interventional Radiology: Contrast Agent
13 November 2023
A Contrast agent, also known as a contrast medium, is a specific substance that is introduced into the human body for the purpose of medical imaging – it is used to alter the contrast of images of parts of the body.
Read →